Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, J. Hans DeVries, Ludger Rose et al.|The Lancet Diabetes & Endocrinology|2017

Cited by 439